AU2002305323A1 - Fused heterocyclic compounds - Google Patents

Fused heterocyclic compounds

Info

Publication number
AU2002305323A1
AU2002305323A1 AU2002305323A AU2002305323A AU2002305323A1 AU 2002305323 A1 AU2002305323 A1 AU 2002305323A1 AU 2002305323 A AU2002305323 A AU 2002305323A AU 2002305323 A AU2002305323 A AU 2002305323A AU 2002305323 A1 AU2002305323 A1 AU 2002305323A1
Authority
AU
Australia
Prior art keywords
heterocyclic compounds
fused heterocyclic
prevention
bond
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002305323A
Other languages
English (en)
Inventor
Xiaoqi Chen
Kang Dai
Pingchen Fan
Shugui Huang
Leping Li
Jeffrey Thomas Mihalic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2002305323A1 publication Critical patent/AU2002305323A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002305323A 2001-05-04 2002-05-03 Fused heterocyclic compounds Abandoned AU2002305323A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28866501P 2001-05-04 2001-05-04
US60/288,665 2001-05-04
PCT/US2002/013856 WO2002089729A2 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Publications (1)

Publication Number Publication Date
AU2002305323A1 true AU2002305323A1 (en) 2002-11-18

Family

ID=23108101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305323A Abandoned AU2002305323A1 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Country Status (9)

Country Link
US (1) US6858619B2 (https=)
EP (1) EP1392298B1 (https=)
JP (1) JP2004529161A (https=)
AT (1) ATE422887T1 (https=)
AU (1) AU2002305323A1 (https=)
CA (1) CA2446351A1 (https=)
DE (1) DE60231202D1 (https=)
ES (1) ES2319619T3 (https=)
WO (1) WO2002089729A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422887T1 (de) 2001-05-04 2009-03-15 Amgen Inc Kondensierte heterozyklische verbindungen
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002352868A1 (en) * 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
CA2473236A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
US7253179B2 (en) 2002-11-06 2007-08-07 Amgen Inc. Fused heterocyclic compounds
US7727998B2 (en) * 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
TW201040153A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用
JP6274384B2 (ja) * 2012-04-27 2018-02-07 Nok株式会社 メタルガスケット及びその製造方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
EP0596897B1 (en) * 1991-07-05 2002-03-13 Smithkline Becham S.P.A. Hydroisoquinoline derivatives
CN1043766C (zh) 1992-09-29 1999-06-23 东丽株式会社 吲哚衍生物及其制法和它们在制备药物中的应用
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
ES2217533T3 (es) 1997-01-16 2004-11-01 Toray Industries, Inc. Derivados de indolomorfinano y medicamentos/preventivos para transtornos cerebrales.
EP1120872B1 (en) 1998-10-07 2006-12-20 Sharp Kabushiki Kaisha Semiconductor laser
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
EP1298439B1 (en) 2000-07-05 2010-11-24 Takeda Pharmaceutical Company Limited Method for screening mch receptor antagonist/agonist
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
JP2004502423A (ja) 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
CZ20031012A3 (en) 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
HK1054390B (en) 2000-12-22 2006-01-06 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
US7034056B2 (en) 2001-03-21 2006-04-25 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
PE20021081A1 (es) 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery Aril y biaril piperidinas con actividad moduladora mch
ATE422887T1 (de) 2001-05-04 2009-03-15 Amgen Inc Kondensierte heterozyklische verbindungen
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues

Also Published As

Publication number Publication date
US20030023085A1 (en) 2003-01-30
ATE422887T1 (de) 2009-03-15
EP1392298A4 (en) 2005-05-25
WO2002089729A2 (en) 2002-11-14
US6858619B2 (en) 2005-02-22
CA2446351A1 (en) 2002-11-14
DE60231202D1 (de) 2009-04-02
EP1392298B1 (en) 2009-02-18
WO2002089729A3 (en) 2003-04-03
ES2319619T3 (es) 2009-05-11
EP1392298A2 (en) 2004-03-03
JP2004529161A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
AU2002305323A1 (en) Fused heterocyclic compounds
AU2003303210A1 (en) Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
ATE340796T1 (de) Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
AU6226494A (en) Spiroazacyclic derivatives as substance p antagonists
WO2003028641A3 (en) Mch receptor antagonists
HUP0100266A2 (hu) NMDA-receptor-antagonista hatású 1-aminoalkilciklohexánszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és előállításaik
CA2503767A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
MA28111A1 (fr) Derives des
AU2002368152A1 (en) 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
TW200720260A (en) Prokineticin 1 receptor antagonists
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
AU2002353286A1 (en) 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) Flavaxate derivatives as muscarinic receptor antagonists
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
AU2003262926A1 (en) Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
ZA200604748B (en) Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles
WO2001032647A3 (en) Benz`f!indoles for use in the treatment of 5ht receptor related disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase